Distinguished in Leukemia

Dr. Amy E. Dezern

Oncology | Hematology
Johns Hopkins University
5755 Cedar Ln, 
Columbia, MD 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Distinguished in Leukemia
Johns Hopkins University
5755 Cedar Ln, 
Columbia, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Dezern is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Dezern is rated as a Distinguished provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dezern is currently accepting new patients.

Her clinical research consists of co-authoring 221 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 69 articles and participated in 5 clinical trials in the study of Leukemia.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
5755 Cedar Ln, Columbia, MD 21044
Other Locations
JOHNS HOPKINS UNIVERSITY
600 N Wolfe St, Blalock 266, Baltimore, MD 21287
JOHNS HOPKINS UNIVERSITY
5759 Cedar Ln, Columbia, MD 21044

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome
Enrollment Status: Recruiting
Publish Date: August 13, 2025
Intervention Type: Other, Drug
Study Drugs: Azacitidine, Enasidenib
Study Phase: Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
Enrollment Status: Suspended
Publish Date: August 05, 2025
Intervention Type: Drug
Study Drugs: Lenalidomide, Luspatercept
Study Phase: Phase 1/Phase 2
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Enrollment Status: Terminated
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: SY-1425+Azacitidine, Azacitidine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes
A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes
Enrollment Status: Completed
Publish Date: March 10, 2023
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Thymoglobulin, Fludarabine, Cyclophosphamide, Mesna, Tacrolimus, Mycophenolic Acid Mofetil
Study Phase: Phase 2
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: APR-246, Azacitidine
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

221 Total Publications

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.
A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.
Journal: bioRxiv : the preprint server for biology
Published: September 02, 2025
Similar Doctors
Elite in Leukemia
Dr. Mark J. Levis
Oncology
Elite in Leukemia
Dr. Mark J. Levis
Oncology

Johns Hopkins University

8600 Old Georgetown Rd, 
Bethesda, MD 
 (19.2 miles away)
301-896-3100
Languages Spoken:
English
See accepted insurances

Mark Levis is an Oncologist in Bethesda, Maryland. Dr. Levis is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Elite in Leukemia
Dr. Adrian U. Wiestner
Hematology
Elite in Leukemia
Dr. Adrian U. Wiestner
Hematology
10 Center Dr, 
Bethesda, MD 
 (18.7 miles away)
301-594-6855
Languages Spoken:
English
See accepted insurances

Adrian Wiestner is a Hematologist in Bethesda, Maryland. Dr. Wiestner is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, and Small Lymphocytic Lymphoma (SLL).

Distinguished in Leukemia
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology
Distinguished in Leukemia
Dr. Bruce D. Cheson
Hematology | Hematology Oncology | Oncology

American Oncology Partners PA

6410 Rockledge Dr, Suite 660, 
Bethesda, MD 
 (18.6 miles away)
301-571-0019
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Bruce Cheson is a Hematologist and a Hematologist Oncology provider in Bethesda, Maryland. Dr. Cheson is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Follicular Lymphoma, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant. Dr. Cheson is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dezern's expertise for a condition
ConditionClose
View All 13 Distinguished Conditions
View All 10 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile